Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ATRA

Atara Biotherapeutics Inc

Sep 13 • 01:24PM ET

9.26

Dollar change +1.18
Percentage change 14.54	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF SCHA FESM BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-39.12	Insider Own	34.21%	Shs Outstand	4.26M	Perf Week	-2.27%
Market Cap	52.48M	Forward P/E	-	EPS next Y	-7.29	Insider Trans	-10.16%	Shs Float	3.73M	Perf Month	19.88%
Income	-181.05M	PEG	-	EPS next Q	-1.72	Inst Own	47.30%	Short Float	11.00%	Perf Quarter	-29.82%
Sales	62.39M	P/S	0.84	EPS this Y	87.05%	Inst Trans	-8.01%	Short Ratio	3.12	Perf Half Y	-41.24%
Book/sh	-22.61	P/B	-	EPS next Y	13.75%	ROA	-99.55%	Short Interest	0.41M	Perf Year	-74.99%
Cash/sh	6.25	P/C	1.48	EPS next 5Y	-	ROE	-2014.86%	52W Range	4.97 - 49.00	Perf YTD	-27.81%
Dividend Est.	50.00 (540.25%)	P/FCF	-	EPS past 5Y	13.12%	ROI	-	52W High	-81.11%	Beta	0.48
Dividend TTM	-	Quick Ratio	0.29	Sales past 5Y	25.21%	Gross Margin	80.14%	52W Low	86.40%	ATR (14)	0.93
Dividend Ex-Date	-	Current Ratio	0.42	EPS Y/Y TTM	-1230.87%	Oper. Margin	-268.10%	RSI (14)	56.72	Volatility	11.39% 9.54%
Employees	225	Debt/Eq	-	Sales Y/Y TTM	809.03%	Profit Margin	-290.20%	Recom	2.60	Target Price	12.75
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-358.31%	Payout	-	Rel Volume	1.73	Prev Close	8.08
Sales Surprise	-22.79%	EPS Surprise	-38.52%	Sales Q/Q	2892.69%	Earnings	Aug 12 AMC	Avg Volume	131.67K	Price	9.26
SMA20	19.86%	SMA50	6.22%	SMA200	-35.06%	Trades		Volume	141,247	Change	14.54%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Downgrade	Mizuho	Buy → Neutral	$31 → $1
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Downgrade	Citigroup	Neutral → Sell	$8 → $3
Jul-13-22	Downgrade	Stifel	Buy → Hold	$16 → $5
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral	$10
May-10-22	Downgrade	Citigroup	Buy → Neutral	$15 → $8
May-13-21	Upgrade	JP Morgan	Neutral → Overweight	$23 → $29
Dec-09-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$28 → $31
Nov-10-20	Reiterated	H.C. Wainwright	Buy	$26 → $28
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy	$25
Apr-23-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral	$43 → $22
Sep-27-19	Downgrade	Goldman	Neutral → Sell	$14 → $9
Sep-16-19	Downgrade	Jefferies	Buy → Hold	$32 → $15
Jun-04-19	Upgrade	Citigroup	Sell → Neutral	$23 → $24
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy

Show Previous Ratings

Sep-06-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.30% -5.28%
Sep-04-24 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) +32.89% +10.50%
Sep-03-24 04:16PM	Atara Biotherapeutics Announces $36 Million Registered Direct Offering (Business Wire) -10.39%
Aug-12-24 06:10PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
05:07PM	Atara Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance)
05:00PM	Loading…
05:00PM	Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update (Business Wire)
Aug-07-24 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire) -9.79%
Jul-19-24 06:12AM	US FDA grants priority review for Pierre Fabres EBV+ PTLD (Pharmaceutical Technology)
Jul-17-24 04:13PM	FDA priority review advances Ataras tabelecleucel for viral infection (Pharmaceutical Technology) -12.82%
09:00AM	Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Business Wire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire) +9.95%
Jul-15-24 12:00PM	All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy (Zacks) +6.59%
Jul-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
Jul-03-24 07:57PM	Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum (Business Wire)
04:01PM	Loading…
Jun-21-24 04:01PM	Atara Biotherapeutics Ebvallo (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases (Business Wire) -7.53%
Jun-17-24 08:00AM	Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split (Business Wire) -16.93%
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire) +7.68%
Jun-07-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.08%
Jun-05-24 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-29-24 04:01PM	Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting (Business Wire) -8.42%
May-20-24 11:57AM	Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise (MT Newswires) +16.39%
09:25AM	Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA (Business Wire)
May-09-24 10:57PM	ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:17PM	Atara Biotherapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress (Business Wire)
May-03-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.00%
Apr-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:53PM	Loading…
Mar-28-24 01:53PM	ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
09:40AM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:40AM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress (Business Wire)
Feb-29-24 09:05AM	Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy (Business Wire)
Feb-28-24 04:30PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 09:00AM	Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis (Business Wire)
Jan-31-24 06:30PM	Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel Data in The Lancet Oncology (Business Wire) +33.10%
Jan-11-24 01:26AM	Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding (GuruFocus.com) +5.31%
01:26AM	Seth Klarman's Exit from Atara Biotherapeutics Inc (GuruFocus.com)
Jan-08-24 09:00AM	Atara Biotherapeutics Announces $15 Million Registered Direct Offering (Business Wire) +25.28%
08:00AM	Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-04-24 04:01PM	Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-20-23 04:01PM	Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories (Business Wire) -19.44%
Dec-11-23 12:00PM	Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting (Business Wire)
Dec-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.10%
Nov-29-23 06:05PM	Atara Biotherapeutics To Present Positive New Tab-cel Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 (Business Wire) +13.36%
Nov-24-23 12:29PM	Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why (Zacks) +13.93%
Nov-22-23 04:01PM	Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire) +13.22%
09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Nov-10-23 04:01PM	Atara Biotherapeutics To Participate at the Stifel Healthcare Conference (Business Wire) +11.88%
Nov-09-23 08:23AM	Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today? (InvestorPlace) -80.17%
06:40AM	Ataras cell therapy approach to MS falls short in study (BioPharma Dive)
Nov-08-23 05:35PM	Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis (Business Wire) -9.02%
Nov-05-23 12:50PM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 05:42AM	Atara Biotherapeutics Inc (ATRA) Announces Q3 2023 Financial Results and Expanded Global Partnership (GuruFocus.com) -5.56%
02:25AM	Q3 2023 Atara Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 08:35AM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results (Business Wire)
Oct-06-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.09%
Sep-21-23 09:19AM	Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study (Zacks)
Sep-19-23 04:01PM	Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability (Business Wire) +11.39%
Sep-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.16%
Aug-31-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference (Business Wire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Aug-08-23 05:30PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -17.18%
04:18PM	Atara Biotherapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress (Business Wire)
Aug-04-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 04:01PM	Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-31-23 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +7.28%
Jul-29-23 11:07AM	10 Stocks That Will Go Up 1000 Percent (Insider Monkey)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace) +6.56%
Jul-07-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.45% +5.41%
Jun-16-23 06:05AM	Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook (Simply Wall St.) -6.07%
Jun-07-23 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire) +13.94%
Jun-05-23 09:00AM	Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023 (Business Wire)
Jun-02-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-18-23 07:09AM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To Be (Simply Wall St.)
May-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -17.85%
04:12PM	Atara Biotherapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress (Business Wire)
May-07-23 08:59AM	The Market Doesn't Like What It Sees From Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Revenues Yet (Simply Wall St.)
May-05-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.82%
May-01-23 04:01PM	Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023 (Business Wire) -8.19%
Apr-16-23 12:08PM	3 Stocks to Buy That Could Be the Next Biotech Breakthrough (InvestorPlace)
Mar-31-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-24-23 09:35AM	Atara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-03-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:40AM	Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year? (Zacks)
Mar-01-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference (Business Wire) -8.44%
Feb-21-23 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference (Business Wire) -9.96%
Feb-15-23 06:58AM	The past five years for Atara Biotherapeutics (NASDAQ:ATRA) investors has not been profitable (Simply Wall St.)
Feb-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.69% -5.36%
04:01PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress (Business Wire)
06:00AM	Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel) (Business Wire)
Feb-06-23 08:00AM	Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023 (Business Wire)
Feb-03-23 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.31%
Jan-13-23 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-23 04:01PM	Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire) +6.27%

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Touchon Pascal	President and CEO	Aug 16 '24	Sale	6.63	3,038	20,139	70,127	Aug 20 06:27 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Aug 16 '24	Sale	6.63	1,821	12,072	34,118	Aug 20 06:27 PM
Murugan Amar	EVP, Chief Legal Officer	Aug 16 '24	Sale	6.63	1,158	7,677	26,827	Aug 20 06:27 PM
Hyllengren Eric J	EVP, CFO	Aug 16 '24	Sale	6.63	1,070	7,093	24,756	Aug 20 06:27 PM
Henrich Jill	EVP, Global Head RA & Quality	Aug 16 '24	Sale	6.63	963	6,384	20,378	Aug 20 06:26 PM
Touchon Pascal	Director	Aug 16 '24	Proposed Sale	8.02	3,525	28,270		Aug 16 04:12 PM
Nguyen AnhCo	Officer	Aug 16 '24	Proposed Sale	8.02	2,114	16,954		Aug 16 04:10 PM
Murugan Amar	Officer	Aug 16 '24	Proposed Sale	8.02	1,342	10,763		Aug 16 04:09 PM
Hyllengren Eric J	Officer	Aug 16 '24	Proposed Sale	8.02	1,239	9,937		Aug 16 04:08 PM
Henrich Jill	Officer	Aug 16 '24	Proposed Sale	8.02	1,113	8,926		Aug 16 04:06 PM
Touchon Pascal	President and CEO	May 16 '24	Sale	0.62	81,506	50,289	1,829,146	May 20 08:34 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	May 16 '24	Sale	0.62	42,899	26,469	898,498	May 20 08:34 PM
Murugan Amar	EVP, Chief Legal Officer	May 16 '24	Sale	0.62	32,401	19,991	695,120	May 20 08:33 PM
Hyllengren Eric J	EVP, CFO	May 16 '24	Sale	0.62	28,648	17,676	645,671	May 20 08:33 PM
Henrich Jill	EVP, Global Head RA & Quality	May 16 '24	Sale	0.62	25,750	15,888	529,251	May 20 08:32 PM
Touchon Pascal	President and CEO	Mar 04 '24	Sale	0.72	24,844	17,888	1,910,652	Mar 06 06:19 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Mar 04 '24	Sale	0.72	10,746	7,737	941,397	Mar 06 06:18 PM
Murugan Amar	EVP, Chief Legal Officer	Mar 04 '24	Sale	0.72	10,044	7,232	727,521	Mar 06 06:18 PM
Henrich Jill	EVP, Global Head RA & Quality	Mar 04 '24	Sale	0.72	3,879	2,793	555,001	Mar 06 06:16 PM
Touchon Pascal	President and CEO	Nov 16 '23	Sale	0.39	20,409	7,939	655,496	Nov 20 05:31 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Nov 16 '23	Sale	0.39	8,856	3,445	277,143	Nov 20 05:31 PM
Murugan Amar	EVP, Chief Legal Officer	Nov 16 '23	Sale	0.39	8,307	3,231	257,084	Nov 20 05:30 PM
Joshi Manher	EVP, Chief Medical Officer	Nov 16 '23	Sale	0.39	12,287	4,780	171,284	Nov 20 05:30 PM
Hyllengren Eric J	SVP, CFO	Nov 16 '23	Sale	0.39	11,958	4,652	205,998	Nov 20 05:29 PM
Henrich Jill	EVP, Global Head RA & Quality	Nov 16 '23	Sale	0.39	3,267	1,271	104,424	Nov 20 05:29 PM
Gallagher Carol Giltner	Director	Nov 13 '23	Buy	0.22	179,020	40,029	368,438	Nov 15 05:07 PM
Gallagher Carol Giltner	Director	Nov 14 '23	Buy	0.31	90,980	28,186	459,418	Nov 15 05:07 PM
HEIDEN WILLIAM K	Director	Nov 10 '23	Buy	0.25	100,000	25,330	209,000	Nov 14 06:29 PM
DOBMEIER ERIC	Director	Nov 10 '23	Buy	0.23	446,825	101,340	563,325	Nov 14 06:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATRA

Atara Biotherapeutics Inc

Upgrade your FINVIZ experience